Syngene International Expands Long-Term Collaboration with Bristol Myers Squibb until 2035

Syngene International and Bristol Myers Squibb: A Partnership for Innovation

In a significant move within the pharmaceutical research sector, Syngene International, a leading global contract research, development, and manufacturing organization (CRDMO) based in India, has announced the extension of its long-standing collaboration with Bristol Myers Squibb (BMS) until 2035. This strategic partnership, which has thrived for over 25 years, is aimed at enhancing the integrated service offerings throughout the drug development cycle.

Founded in 1998, the collaboration has already borne fruit through the establishment of the Biocon Bristol Myers Squibb Research and Development Center (BBRC) in India, which opened its doors in 2009. The BBRC has become a central hub for research and development, significantly contributing to BMS's capabilities in target identification, drug discovery, and development. With approximately 700 scientists dedicated to various aspects of biomedical research, the center has played a pivotal role in expediting the development of new therapeutic compounds.

This extended collaboration will now broaden the scope of services provided, covering aspects from drug discovery, such as chemistry and biology, to clinical trials and pharmaceutical manufacturing, coupled with data and IT services. By fostering a seamless transition from research to commercialization, both Syngene and BMS aim to accelerate the delivery of innovative therapies to the global market.

Comments from Leadership

The extension of this partnership underscores the mutual commitment to scientific excellence and operational reliability. Peter Bains, the CEO of Syngene International, emphasized the importance of long-term planning and capability building, stating, "Our collaboration helps us to plan the future together, ensuring strategic value for both companies. We are thrilled to support BMS in its forthcoming wave of drug discovery, development, and manufacturing programs."

Payal Sheth, BMS's Senior Vice President of Therapeutic Discovery Sciences, echoed this sentiment, highlighting the patient-centric approach that drives their efforts. She noted, "Our collaboration reflects a shared ambition to advance innovative science through the efficient integration of our research, development, and manufacturing capabilities, ultimately enhancing patient outcomes worldwide."

Historical Impact and Future Outlook

The BBRC has been instrumental in streamlining the processes involved in drug development, helping to reduce the timelines and costs associated with bringing new medicines to market. The center not only advances preclinical development but also plays a central role in patent submissions across a range of therapeutic areas, including oncology and immunology.

With over 8,200 employees, including 5,600 scientists, Syngene exemplifies a commitment to delivering high-quality research and development services. The company operates more than 2.5 million square feet of specialized facilities for drug discovery, development, and manufacturing, working with 400 global clients across various sectors, including biotechnology and pharmaceuticals.

As the pharmaceutical landscape continues to evolve, collaborations like that of Syngene and BMS will be pivotal in addressing the pressing healthcare needs of patients globally. The extension of their partnership through 2035 is not just a testament to their successful past but a beacon of their joint vision for a future filled with innovative and effective therapies.

For more details about Syngene International and their commitment to scientific excellence, please visit Syngene's official website. With this significant extension, Syngene and BMS are poised to remain at the forefront of tomorrow's medicine, ensuring that they can bring therapeutic solutions that enhance patient health and quality of life worldwide.